Skip to main content

Table 1 Baseline demographics and clinical characteristics

From: Impact of 6% balanced hydroxyethyl starch following cardiopulmonary bypass on renal function: a retrospective study

Variables

Low dose HES

(n = 1239)

Moderate dose HES

(n = 418)

p-value

Age

58.2 ± 13.6

59.4 ± 14.6

< .001

Female gender

503 (40.6)

251 (60.5)

.16

Diabetes mellitus

188 (15.9)

66 (15.7)

.76

Hypertension

514 (41.5)

163 (39.0)

.36

Cerebrovascular accident

65 (5.2)

18 (4.3)

.44

Euro score

2.6 ± 4.1

2.8 ± 4.8

.08

LV ejection fraction, %

58.7 ± 10.2

58.8 ± 10.5

.77

Medication

 Angiotensin receptor blockers

410 (33.1)

140 (33.5)

.88

 Diuretics

483 (38.9)

177 (42.3)

.22

 Insulin

121 (9.7)

35 (8.3)

.39

 Statins

404 (32.6)

144 (34.4)

.48

Laboratory

 Hemoglobin, g/dL

12.9 ± 1.9

12.5 ± 1.8

< .001

 Creatinine, mg/dL

0.89 (0.75, 1.06)

0.84 (0.69, 1.01)

< .001

 Total bilirubin, mg/dL

0.5 (0.4, 0.8)

0.5 (0.4, 0.8)

.94

  1. Results are presented as mean ± SD or median (IQR) as appropriate and number (percentage)
  2. HES Hydroxyethyl starch; LV Left ventricle